BIO Digital

June 10-11 & 14-18, 2021

Spotlight on: Samsung Biologics

Search General Info
Search Education
Search Partnering Companies

Spotlight on: Samsung Biologics

Samsung Biologics is a fully integrated CDMO offering a mammalian cell line & process development to cGMP clinical & commercial manufacturing (DS/DP) and biosafety testing services, all from a single location. We provide highly tailored solutions to each client in need.

Established in April 2011, Samsung Biologics' core business activities include Upstream & Downstream Process Development, Clinical & Commercial manufacturing, Aseptic Fill/Finish, and Analytical & Biosafety testing. With our manufacturing sites located in South Korea, all plants are cGMP compliant holding 364KL total capacity with flexible clinical & commercial scales of 1KL, 5KL, 15KL.

With a dedicated Quality Control Lab & Process Development Unit and designed as multi-product facilities to meet the requirements of the US FDA, EMA, and other global regulatory agencies. Recently, 4KL of Single-use bioreactors have added, which provides us further flexibility to accommodate a wide range of clients' demands.


Sessions Featuring Samsung Biologics

Samsung Biologics' Company Presentation: 
Key Considerations for Successful Technology Transfer (Andrew Kim, Associate Director of DSP MSAT)

BioProcess International Theater Sessions:


And don't forget to meet Samsung Biologics in BIO One-on-One Partnering during BIO Digital Week.